2010 | 2009 | 2008                                                      DSPA 2009 Press Releases

Date	Title
12/17/09	Sepracor Granted Patent Term Extension for LUNESTA® and Provides Update on LUNESTA Pediatric Studies
12/07/09	New STEDESA™ Clinical Data Presented at American Epilepsy Society Annual Meeting in Boston
12/02/09	Sepracor to Present New STEDESA™ Clinical Data at American Epilepsy Society Annual Meeting
10/26/09	Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
10/26/09	Sepracor Announces Tender Offer for 0% Series B Convertible Senior Subordinated Notes Due 2010
10/20/09	Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc
10/20/09	Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Completion of Subsequent Offering Period and Exercise of Top-Up Option
10/14/09	Dainippon Sumitomo Pharma Co., Ltd. and Sepracor Inc. Announce Successful Tender Offer and Commencement of Subsequent Offering Period
09/24/09	Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period
09/03/09	Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion
08/10/09	Sepracor Announces New Drug Submission (NDS) to Health Canada for STEDESA™ as Adjunctive Treatment for Epilepsy
07/24/09	Sepracor Inc. Reports Strong Second Quarter 2009 Operating Results and Increases Financial Guidance for 2009
07/20/09	Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2009 Operating Results
07/01/09	Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA® Pediatrics
06/01/09	Sepracor's STEDESA™ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA
04/30/09	Sepracor Reports Strong First Quarter 2009 Operating Results and Reiterates Financial Guidance for 2009
04/27/09	Sepracor Reports Preliminary Phase III Study Results for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis
04/23/09	Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2009 Operating Results
04/17/09	Sepracor Announces Patent Interference Proceedings (and Schedule) Against Wyeth for Claims Related to O-desmethylvenlafaxine Succinate (Marketed as PRISTIQ®)
03/31/09	Sepracor Announces Submission of STEDESA™ New Drug Application to FDA for Adjunctive Treatment of Epilepsy
03/20/09	Sepracor Files Patent Infringement Lawsuit Against Eszopiclone ANDA Filers
03/17/09	Sepracor Completes Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
03/10/09	Sepracor Announces Final Settlement of XOPENEX® Inhalation Solution Patent Infringement Litigation with Barr Laboratories, Inc. and Grant of Non-Exclusive License to Barr and Teva Pharmaceuticals USA, Inc.
03/05/09	Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder
02/17/09	Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024
01/28/09	Sepracor Reports Fourth Quarter and Full-Year 2008 Operating Results
01/28/09	Sepracor Announces Strategic Corporate Restructuring and Workforce Reduction Plan in Addition to 2009 Financial Guidance
01/23/09	Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2008 Operating Results